Betifisolimab Biosimilar – Anti-CD274 mAb – Research Grade

Introduction

Betifisolimab Biosimilar, also known as Anti-CD274 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody drug, Nivolumab. This biosimilar is designed to target the immune checkpoint protein, CD274, which is involved in regulating the immune response. Betifisolimab Biosimilar is a research grade antibody that has shown promising results in pre-clinical studies and is being further evaluated for its potential therapeutic applications.

Structure of Betifisolimab Biosimilar

Betifisolimab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions are responsible for binding to the target protein, CD274, while the constant regions determine the antibody’s effector functions.

Activity of Betifisolimab Biosimilar

Betifisolimab Biosimilar works by binding to CD274, also known as programmed death-ligand 1 (PD-L1), on the surface of cancer cells. CD274 is an immune checkpoint protein that plays a role in suppressing the immune response. When CD274 binds to its receptor, PD-1, on immune cells, it inhibits their activity and prevents them from attacking cancer cells. By binding to CD274, Betifisolimab Biosimilar blocks this interaction and allows the immune cells to recognize and attack cancer cells.

Application of Betifisolimab Biosimilar

Betifisolimab Biosimilar has shown promising results in pre-clinical studies as a potential treatment for various types of cancer, including lung cancer, melanoma, and bladder cancer. It is being evaluated as a monotherapy and in combination with other cancer treatments. Betifisolimab Biosimilar has also shown potential in treating other diseases, such as rheumatoid arthritis and inflammatory bowel disease, which are associated with overactive immune responses.

Antibody Therapy and Immune Checkpoint Inhibitors

Antibody therapy is a type of cancer treatment that uses monoclonal antibodies to target specific proteins on cancer cells. Immune checkpoint inhibitors, such as Betifisolimab Biosimilar, are a type of antibody therapy that targets immune checkpoint proteins, which play a role in suppressing the immune response. By blocking these proteins, immune checkpoint inhibitors allow the immune system to recognize and attack cancer cells.

Therapeutic Target: CD274

CD274, also known as PD-L1, is a protein that is expressed on the surface of cancer cells and other cells in the body. It is a key regulator of the immune response and plays a role in preventing the immune system from attacking healthy cells. However, cancer cells can take advantage of this protein to evade the immune system and continue to grow and spread. By targeting CD274, Betifisolimab Biosimilar aims to restore the immune system’s ability to recognize and eliminate cancer cells.

Conclusion

Betifisolimab Biosimilar, also known as Anti-CD274 mAb, is a research grade monoclonal antibody that targets the immune checkpoint protein, CD274, on cancer cells. By blocking the interaction between CD274 and its receptor on immune cells, Betifisolimab Biosimilar allows the immune system to recognize and attack cancer cells. It has shown promising results in pre-clinical studies and is being further evaluated as a potential treatment for various types of cancer and other diseases associated with overactive immune responses.